Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal...
Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts
About this item
Full title
Author / Creator
Publisher
Oxford, UK: Blackwell Publishing Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Oxford, UK: Blackwell Publishing Ltd
Subjects
More information
Scope and Contents
Contents
MCC‐465 is an immunoliposome‐encapsulated doxorubicin. The liposome is tagged with polyethylene glycol and the F(ab)2 of a monoclonal antibody named GAH, a human antibody obtained by the hybridoma technique. The epitope recognized by GAH is not well characterized, but human gastric, colorectal, and mammary cancer cells were GAH‐positive, while the...
Alternative Titles
Full title
Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11159757
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11159757
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/j.1349-7006.2004.tb02495.x
